Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs CK 0801 (Primary)
- Indications Aplastic anaemia; Bone marrow disorders; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- Sponsors Cellenkos
- 10 Dec 2018 Status changed from planning to not yet recruiting.
- 24 Oct 2018 New trial record
- 16 Oct 2018 According to a Cellenkos media release, the company holds an approved FDA IND to proceed with this trial.